Scribe Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
View original at finance.yahoo.com“Cash, cash equivalents, and marketable securities of $174.2 million as of September 30, 2026, provide funding into the first half of 2029”
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Current LDL-C lowering therapies are limited by poor persistence and adherence, with studies showing 50% to 70% of patients discontinue treatment within one year.
60% confidenceQ3 was a period of continued execution for Scribe, marked by the completed IPO and the expansion of the Sanofi collaboration to include the epigenetic silencing technology, which strengthen the Company's foundation for translating its technologies into medicines.
60% confidenceIndividuals with naturally occurring PCSK9 loss-of-function variants have been reported to have 28% lower mean LDL-C levels and up to 88% lower coronary heart disease risk; STX-1150 aims to mimic this protection and could shift LDL-C management from chronic treatment to long-term prevention.
60% confidenceCash, cash equivalents and marketable securities of $174.2 million as of September 30, 2026 provide funding into the first half of 2029.
60% confidenceInitial clinical data from the STX-1150 Phase 1 trial are expected in the first half of 2027.
60% confidence
